Blueprint Medicines (BPMC) AI Stock Analysis

• Market Cap: $8.29B
• Dividend Yield: N/A
• Average Volume (3M): 4.48M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.30
• Revenue Growth: 99.19%
• EPS Growth: 48.43%
• Country: US
• Employees: 682
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): 0.01
• Shares Outstanding: 64,666,115
• 10 Day Avg. Volume: 4,448,629
• 30 Day Avg. Volume: 4,475,931
• PEG Ratio: 0.31
• Price to Book (P/B): 5.08
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -5.11
• Enterprise Value/Market Cap: 0.33
• Enterprise Value/Revenue: 1.46
• Enterprise Value/Gross Profit: 5.08
• Enterprise Value/Ebitda: -3.19
• 1Y Price Target: $131.00
• Price Target Upside: 2.02% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 19

• Rating: 50 Neutral
• Price Target: $128.00 ▼(-0.31%Downside)

Blueprint Medicines' overall score is primarily impacted by its strong financial growth potential and positive earnings call sentiment. However, profitability challenges and an overvalued stock, as indicated by the P/E ratio, weigh heavily on the score. Technical indicators show a bullish trend, but potential overbought conditions warrant caution. The corporate merger event, while positive, is excluded from weighted scoring but is a significant strategic advantage.

Positive Factors

Acquisition Strategy

Sanofi's acquisition of Blueprint Medicines complements its portfolio in rare disease and immunology, enhancing strategic growth.

Financial Performance

Sanofi expects the acquisition to be immediately accretive to gross margin and accretive to operating income and EPS after 2026.

Negative Factors

Competition

The timing of the acquisition announcement is curious given the expected pivotal data from Cogent’s SUMMIT trial, which could impact Blueprint's systemic mastocytosis franchise.

Market Concerns

Macro issues affecting biotech, such as pricing and tariffs, remain a concern for investors.

Blueprint Medicines Business Overview & Revenue Model

Company Description

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Blueprint Medicines makes money primarily through the development and commercialization of its proprietary drug therapies. The company's revenue model includes product sales, particularly from its FDA-approved therapies like AYVAKIT (avapritinib) and GAVRETO (pralsetinib), which target specific genetic mutations in cancer patients. Additionally, Blueprint Medicines generates revenue through collaborations and licensing agreements with other pharmaceutical companies, which may include upfront payments, milestone payments, and royalties on sales generated by partner-developed products. Strategic partnerships and collaborations, such as those with Roche and CStone Pharmaceuticals, are significant contributors to its earnings by enhancing its research capabilities and extending its market reach.

Blueprint Medicines Financial Statement Overview

Summary

Blueprint Medicines demonstrates strong revenue growth but remains unprofitable, with significant challenges in cash flow management and operational efficiency. The balance sheet is stable with manageable debt levels, though profitability metrics are concerning.

Income Statement

Blueprint Medicines has shown a notable increase in revenue over recent years, indicating strong growth potential with a revenue growth rate of 10.46% TTM. However, the company remains unprofitable with a negative net profit margin of -27.69% and negative EBIT and EBITDA margins, reflecting ongoing challenges in cost management and operational efficiency.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio of 0.36 TTM, indicating manageable debt levels. However, the return on equity remains problematic at -45.51%, reflecting negative profitability. The equity ratio of 28.62% suggests a stable asset base, although the reliance on equity financing could be improved.

Cash Flow

Blueprint Medicines faces challenges with cash flow, as indicated by negative free cash flow and a deteriorating free cash flow growth rate of 23.45% TTM. The operating cash flow to net income ratio is negative, highlighting cash flow pressures and the need for improved cash management strategies.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
562.12M	508.82M	249.38M	204.04M	180.08M	793.74M
	Gross Profit
538.73M	488.66M	236.58M	186.22M	162.15M	793.31M
	EBIT
-174.31M	-212.04M	-486.28M	-549.25M	-648.46M	302.15M
	EBITDA
-131.05M	19.23M	-470.36M	-515.41M	-628.30M	308.71M
	Net Income Common Stockholders
-155.73M	-67.09M	-506.98M	-557.52M	-644.09M	313.88M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
576.24M	615.49M	710.64M	1.08B	1.03B	1.55B
	Total Assets
1.20B	1.18B	1.05B	1.35B	1.25B	1.72B
	Total Debt
122.75M	469.11M	774.12M	242.45M	111.41M	89.60M
	Net Debt
504.00K	367.09M	702.84M	122.74M	-98.54M	-595.03M
	Total Liabilities
853.47M	881.15M	918.64M	835.23M	281.49M	248.31M
	Stockholders Equity
342.13M	298.67M	130.61M	514.68M	970.74M	1.47B
Cash Flow		Free Cash Flow
-150.91M	-197.22M	-452.91M	-511.20M	-559.89M	383.88M
	Operating Cash Flow
-145.55M	-192.59M	-436.85M	-502.28M	-298.65M	387.04M
	Investing Cash Flow
-59.55M	-47.50M	274.04M	-149.54M	-225.86M	-434.25M
	Financing Cash Flow
215.34M	273.11M	119.22M	561.81M	50.72M	617.76M

Blueprint Medicines Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 128.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BPMC, the sentiment is Positive. The current price of 128.4 is above the 20-day moving average (MA) of 121.09, above the 50-day MA of 104.25, and above the 200-day MA of 96.01, indicating a bullish trend. The MACD of 7.37 indicates Positive momentum. The RSI at 75.84 is Negative, neither overbought nor oversold. The STOCH value of 80.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BPMC.

Blueprint Medicines Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALKS	77 Outperform	$4.80B	13.93	25.71%	―	-12.31%	-17.53%
BBIO	60 Neutral	$7.92B	―	35.68%	―	-41.71%	-9.37%
SRPT	54 Neutral	$1.97B	19.61	-23.61%	―	59.15%	-1881.09%
AXSM	54 Neutral	$4.96B	―	-282.16%	―	72.16%	9.65%
RVMD	52 Neutral	$7.39B	―	-36.68%	―	-100.00%	5.49%
Sector *	51 Neutral	$7.34B	0.29	-60.38%	2.38%	17.46%	1.71%
BPMC	50 Neutral	$8.29B	―	-47.71%	―	99.19%	48.43%

Blueprint Medicines Corporate Events

Blueprint Medicines Holds Annual Stockholders Meeting

On June 18, 2025, Blueprint Medicines held its Annual Meeting of Stockholders where several key decisions were made. Jeffrey W. Albers, Mark Goldberg, M.D., and John Tsai, M.D. were elected as Class I directors for a three-year term. Additionally, stockholders approved the compensation for named executive officers and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions reflect the company’s ongoing governance and operational strategies, potentially impacting its leadership stability and financial oversight.

The most recent analyst rating on (BPMC) stock is a Buy with a $135.00 price target. To see the full list of analyst forecasts on Blueprint Medicines stock, see the BPMC Stock Forecast page.

Blueprint Medicines Announces Merger Agreement with Sanofi

On June 2, 2025, Blueprint Medicines Corporation entered into a merger agreement with Sanofi, under which Sanofi will acquire Blueprint for approximately $9.1 billion in cash, with additional contingent value rights potentially increasing the total value to $9.5 billion. This acquisition is expected to enhance Sanofi’s portfolio in rare immunological diseases by adding Blueprint’s approved medicine for systemic mastocytosis and its early-stage immunology pipeline, thereby strengthening Sanofi’s position in the immunology sector.

The most recent analyst rating on (BPMC) stock is a Buy with a $135.00 price target. To see the full list of analyst forecasts on Blueprint Medicines stock, see the BPMC Stock Forecast page.